本文转自【央视新闻微信公众号】； 近日，北京的一位患儿在甲流退烧后的第3天，因为骑车运动一小时，产生呼吸不畅等症状，送医后被 诊断为心肌损伤。什么是心肌损伤？为什么退烧后运动会导致这类疾病？ 为什么流感退烧数日后 仍会引发心肌炎？ 医生介绍，心肌损伤是心肌炎的后果之一，心肌细胞受损后，化验单会显示心肌酶学升高，可能出现心 率过快或过慢，严重时超声可见心功能下降，这些都是心肌损伤的表现，心肌炎患者会出现不同形式的 心肌损伤。 为什么流感退烧好几天了，还会引发心肌炎？医生表示—— 呼吸道、消化道病毒感染后，由于儿童的各个器官和系统的免疫功能尚未成熟，病毒感染引发的病毒血 症会侵犯心肌，从而出现心肌炎。 病毒感染引发的全身损伤，一般来说有一周的自然病程，退烧后病毒损伤并没有完全停止，仍可能出现 心肌炎。 心肌炎可轻可重 警惕暴发性心肌炎 记者在采访中了解到，心肌炎的病程通常分为"炎症风暴"和"自身免疫"两个阶段。 第一阶段，病毒感染后发热，这是体内"炎症风暴"阶段，会出现呼吸道或肠道症状，"炎症风暴"会损伤 心肌； 退热后的第二阶段为"免疫阶段"，这个阶段的损伤可能更重，身体产生的抗体不仅攻击病毒，还会误将 感染的 ...

Core Viewpoint - Mingyu Pharmaceutical Co., Ltd. has submitted an application for a mainboard listing on the Hong Kong Stock Exchange, with Morgan Stanley, Bank of America, and CITIC Securities as joint sponsors [1] Company Overview - Established in 2018, Mingyu Pharmaceutical is a biotechnology innovation company nearing commercialization, employing a dual-engine development strategy of "tumor immunity + autoimmune" [1] - The company has 13 drug candidates in development, with 10 in clinical stages, featuring a diverse product pipeline that includes ADC drugs, bispecific antibodies, and autoimmune therapies [1] Product Pipeline - In the oncology sector, the core product TROP-2 ADC drug MHB036C targets a multi-billion dollar solid tumor market and is currently undergoing combination therapy studies with PD-1/VEGF bispecific antibody MHB039A, including Phase I/II studies for non-small cell lung cancer and Phase II studies for breast cancer [1] - Another core product, B7-H3 ADC drug MHB088C, has entered Phase III clinical trials for second-line monotherapy in small cell lung cancer and is also being studied in combination with MHB039A [1] - In the autoimmune sector, the core product IGF-1R antibody MHB018A is in Phase III trials for active thyroid eye disease, while topical JAK inhibitor MH004 is set to submit a new drug application for atopic dermatitis in China by 2025 [1] Financial Performance - Financial data shows that the company reported revenues of 0 yuan for 2023 and 2024, with projected revenue of 264 million yuan for the first half of 2025, primarily from licensing B7-H3 ADC drug rights to Qilu Pharmaceutical, valued at 1.345 billion yuan [2] - R&D expenditures for the same periods were 182 million yuan, 281 million yuan, and 98 million yuan, with a cumulative net loss of 587 million yuan [2] Market Potential - According to a report by Zhi Shi Consulting, the global PD-(L)1 bispecific antibody market is expected to grow from 300 million USD in 2024 to 19.16 billion USD by 2035, with the Chinese market projected to reach 3.37 billion USD by 2035 [2] Funding and Valuation - Mingyu Pharmaceutical has completed five rounds of financing, with notable investors including Aobo Capital, Qiming Venture Partners, Huazhong Fund, Tigermed, and IDG Capital [2] - Following a 131 million USD Series C financing round in July 2025, the post-money valuation of the company reached 3.936 billion yuan [2] - The shareholding structure indicates that Dr. Cao Guoqing and his wife collectively hold 36.27% of the shares [2] Use of Proceeds - The funds raised from the Hong Kong listing will primarily be used for core product R&D, production capacity building, commercialization efforts, and working capital supplementation [2]

Core Viewpoint - Tianjing Bio (IMAB) is focused on developing innovative biopharmaceuticals in the fields of tumor immunology and autoimmune diseases, aiming to fill clinical treatment gaps and improve patient survival globally [1]. Financial Performance - As of December 31, 2023, Tianjing Bio reported total revenue of 27.644 million RMB, representing a year-on-year increase of 112.48% [1]. - The company recorded a net profit attributable to shareholders of -1.466 billion RMB, which is a year-on-year increase of 41.54% [1]. Upcoming Events - Tianjing Bio is scheduled to disclose its fiscal year 2024 interim report on August 28, 2023, before the market opens in the Eastern US [1]. Company Overview - Tianjing Bio is an offshore holding company registered abroad, operating through its domestic subsidiary, focusing on developing innovative biopharmaceuticals with "first-in-class" and "best-in-class" potential [1]. - The company's mission is to create groundbreaking innovative biopharmaceuticals that address unmet clinical needs and significantly enhance the quality of life for patients worldwide [1].

Core Viewpoint - Tianjing Bio (IMAB) has shown significant financial growth, with a notable increase in revenue and a focus on innovative biopharmaceuticals in the oncology and autoimmune sectors [1][2]. Financial Performance - As of December 31, 2023, Tianjing Bio reported total revenue of 27.644 million RMB, representing a year-on-year increase of 112.48% [1]. - The company's net profit attributable to shareholders was -1.466 billion RMB, which reflects a year-on-year improvement of 41.54% [1]. Company Overview - Tianjing Bio is an offshore holding company that operates through its domestic subsidiary, focusing on developing innovative biopharmaceuticals with "first-in-class" and "best-in-class" potential [2]. - The company's mission is to create groundbreaking biopharmaceuticals that address unmet clinical needs and improve the quality of life for patients globally [2]. - Tianjing Bio aims to establish itself as a leading biopharmaceutical company rooted in China and oriented towards global markets [2].

Core Viewpoint - Tianjing Bio (IMAB) has shown significant financial growth, with a notable increase in revenue and a focus on innovative biopharmaceuticals in the oncology and autoimmune sectors [1][2]. Financial Performance - As of December 31, 2023, Tianjing Bio reported total revenue of 27.644 million RMB, representing a year-on-year growth of 112.48% [1]. - The company's net profit attributable to shareholders was -1.466 billion RMB, which reflects a year-on-year increase of 41.54% [1]. Company Overview - Tianjing Bio is an offshore holding company that operates through its domestic subsidiary, focusing on the development of innovative biopharmaceuticals with "first-in-class" and "best-in-class" potential [2]. - The company's mission is to develop groundbreaking biopharmaceuticals that address unmet clinical needs and improve the quality of life for patients globally [2]. - Tianjing Bio aims to establish itself as a leading biopharmaceutical company rooted in China and oriented towards global markets [2].

Core Viewpoint - Tianjing Bio (IMAB) has shown significant financial growth, with a notable increase in revenue and a focus on innovative biopharmaceuticals in the oncology and autoimmune sectors [1] Financial Performance - As of December 31, 2023, Tianjing Bio reported total revenue of 27.644 million RMB, representing a year-on-year increase of 112.48% [1] - The company's net profit attributable to shareholders was -1.466 billion RMB, which reflects a year-on-year improvement of 41.54% [1] Upcoming Events - Tianjing Bio is scheduled to disclose its fiscal year 2024 mid-term report on August 28, 2023, before the market opens in the Eastern US [1] Company Overview - Tianjing Bio is an offshore holding company that operates through its domestic subsidiary, focusing on the development of innovative biopharmaceuticals with "first-in-class" and "best-in-class" potential [1] - The company's mission is to develop groundbreaking biopharmaceuticals that address unmet clinical needs and improve the quality of life for patients globally [1] - Tianjing Bio aims to establish itself as a leading biopharmaceutical company rooted in China and oriented towards global markets [1]

Group 1 - The stock price of Tianjing Biological (IMAB) increased by 11.01% on August 6, reaching $3.741 per share, with a trading volume of $4.6017 million and a total market capitalization of $430 million [1] - As of December 31, 2023, Tianjing Biological reported total revenue of 27.644 million RMB, representing a year-on-year growth of 112.48%, while the net profit attributable to the parent company was -1.466 billion RMB, showing a year-on-year increase of 41.54% [1] Group 2 - Tianjing Biological is scheduled to disclose its fiscal year 2024 interim report on August 28, with the actual disclosure date subject to the company's announcement [2] - The company is an offshore holding parent company that operates through its domestic subsidiary, focusing on innovative biopharmaceuticals in the fields of tumor immunity and autoimmune diseases [2] - Tianjing Biological aims to develop innovative biopharmaceuticals with "first-in-class" and "best-in-class" potential globally, striving to fill clinical treatment gaps and improve the quality of life for patients worldwide [2]

Group 1 - The core viewpoint of the articles highlights the financial performance and upcoming reporting of Tianjing Biological (IMAB), indicating a significant revenue growth and a focus on innovative biopharmaceuticals in oncology and autoimmune diseases [1][2][3] Group 2 - As of August 5, Tianjing Biological's stock opened at $3.01 per share, with a market capitalization of $246 million and a trading volume of $496,100 [1] - For the fiscal year ending December 31, 2023, Tianjing Biological reported total revenue of 27.644 million RMB, representing a year-on-year increase of 112.48%, while the net profit attributable to shareholders was -1.466 billion RMB, showing a year-on-year increase of 41.54% [1] - Tianjing Biological is a company focused on developing innovative biopharmaceuticals with "first-in-class" and "best-in-class" potential, aiming to address unmet clinical needs and improve the quality of life for patients globally [2]

Core Viewpoint - Tianjing Bio (IMAB) has shown significant stock price movement and financial performance, indicating potential growth in the biopharmaceutical sector focused on innovative therapies for cancer and autoimmune diseases [1][2]. Financial Performance - As of December 31, 2023, Tianjing Bio reported total revenue of 27.644 million RMB, representing a year-on-year increase of 112.48% [1]. - The company recorded a net profit attributable to shareholders of -1.466 billion RMB, which is a 41.54% increase compared to the previous year [1]. Upcoming Events - Tianjing Bio is scheduled to disclose its fiscal year 2024 mid-term report on August 28, 2023, before the market opens in the Eastern US [2]. Company Overview - Tianjing Bio is an offshore holding company that operates through its domestic subsidiary, focusing on innovative biopharmaceuticals in the fields of tumor immunology and autoimmune diseases [2]. - The company's mission is to develop groundbreaking innovative biopharmaceuticals that address unmet clinical needs and improve the quality of life for patients globally [2].

Core Insights - Tianjing Bio (IMAB) experienced a stock price increase of 11.14% on July 30, reaching $1.889 per share, with a total market capitalization of $154 million [1] - The company reported total revenue of 27.644 million RMB for the year ending December 31, 2023, representing a year-on-year growth of 112.48%, while the net profit attributable to shareholders was -1.466 billion RMB, showing a year-on-year increase of 41.54% [1] Company Overview - Tianjing Bio is an offshore holding company that operates through its domestic subsidiary, focusing on innovative biopharmaceuticals in the fields of tumor immunology and autoimmune diseases [2] - The company's mission is to develop groundbreaking innovative biopharmaceuticals that address unmet clinical needs and improve the quality of life for patients globally [2] - Tianjing Bio aims to establish itself as a leading biopharmaceutical company rooted in China and oriented towards global markets [2]